These patients were administered doses ranging from 15 to 30 mg/day of pegvisomant over a period ranging from 14 to 23 months and analyzed metabolic parameters, including IGF-1 levels, HbA1c, and FPG, which demonstrated that pegvisomant effectively improves IR in individuals with acromegaly irrespective of any weight loss experienced by the patients [29]. The gene discussed is IGF1; the disease is acromegaly.